Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2015 16:15 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12

FLEMINGTON, N.J., May 14, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for the...
May 13, 2015 17:30 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics Announces Data Validating Continued Onapristone and Companion Diagnostic Development at ASCO Annual Meeting 2015

FLEMINGTON, N.J., May 13, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and...
May 07, 2015 08:30 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics Receives USPTO Notice of Allowance for Two Important Patents Covering Lead Compound Onapristone

Patents to Cover Methods of Use and Diagnostic Methods for Identifying Anti-Progestin Sensitive Tumors Issuance Will Ensure Comprehensive Protection of Onapristone FLEMINGTON, N.J. , May 7,...
April 30, 2015 08:30 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases

FLEMINGTON, N.J., April 30, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for the...
April 29, 2015 08:30 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics to Present Three Posters Supporting Onapristone Development at ASCO Annual Meeting 2015

FLEMINGTON, N.J., April 29, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer...
April 21, 2015 08:30 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics to Present Promising Data From Phase I Trial of Onapristone at AACR Annual Meeting 2015

FLEMINGTON, N.J., April 21, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer...
April 13, 2015 08:30 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics Announces Three Poster Presentations at Upcoming AACR Annual Meeting 2015

FLEMINGTON, N.J., April 13, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer...
March 31, 2015 16:38 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics Reports Fourth Quarter 2014 Financial and Business Update

FLEMINGTON, N.J., March 31, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development therapeutics for cancer and other life...
March 24, 2015 08:30 ET | Source: Arno Therapeutics Inc.

New Data Supporting Arno Therapeutics' HDAC Inhibitor AR-42 Published in The Journal of Urology

FLEMINGTON, N.J., March 24, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics,...
January 08, 2015 08:30 ET | Source: Arno Therapeutics Inc.

Arno Therapeutics to Present at 11th Annual Noble Equity Conference

FLEMINGTON, N.J., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today...